HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells.

Abstract
Modern anti-HER2 antibody therapy tends to exploit a panel of different antibodies against different epitopes on the antigen. For this aim, nanobodies are very striking targeting agents and can be easily produced against any cell-specific membrane antigen. The oligoclonal nanobodies can be used to block more than one functional epitope on a target antigen and inhibit the generation of escape variants associated with cancer therapy. In this study, 12 nanobody clones selected from an immune camel library were examined for their ability to differ between tumor markers. These oligoclonal nanobodies targeted breast cancer cells better than each individual nanobody. In epitope mapping, several nanobodies overlapped in the epitope recognized by trastuzumab and some of the non-overlapping nanobodies could affect the binding of trastuzumab to HER2. This study demonstrates that the oligoclonal nanobodies are potential therapeutic tools that can be used instead of, or in combination with trastuzumab to assess tumor viability during treatment.
AuthorsFatemeh Rahimi Jamnani, Fatemeh Rahbarizadeh, Mohammad A Shokrgozar, Davoud Ahmadvand, Fereidoun Mahboudi, Zahra Sharifzadeh
JournalExperimental cell research (Exp Cell Res) Vol. 318 Issue 10 Pg. 1112-24 (Jun 10 2012) ISSN: 1090-2422 [Electronic] United States
PMID22440788 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Epitopes
  • Immunoglobulin Fragments
  • Immunoglobulin Heavy Chains
  • Peptide Library
  • Recombinant Proteins
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
Topics
  • Animals
  • Antibodies, Monoclonal, Humanized (chemistry)
  • Antibody Affinity
  • Antibody Specificity
  • Antineoplastic Agents (chemistry)
  • Binding, Competitive
  • Camelus
  • Cell Line, Tumor
  • Enzyme-Linked Immunosorbent Assay
  • Epitopes (chemistry, immunology)
  • Flow Cytometry
  • Humans
  • Immunoglobulin Fragments (biosynthesis, chemistry, isolation & purification)
  • Immunoglobulin Heavy Chains (biosynthesis, chemistry, isolation & purification)
  • Mice
  • Peptide Library
  • Protein Binding
  • Receptor, ErbB-2 (chemistry, immunology, metabolism)
  • Recombinant Proteins (biosynthesis, isolation & purification)
  • Trastuzumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: